Welcome to our dedicated page for Minerva Neurosci SEC filings (Ticker: NERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Minerva Neurosciences, Inc. (Nasdaq: NERV) SEC filings page on Stock Titan consolidates the company’s regulatory documents from EDGAR with AI-powered summaries to help readers interpret complex disclosures. As a clinical-stage biopharmaceutical company focused on central nervous system (CNS) diseases, Minerva uses its SEC reports to describe the status of its lead drug candidate roluperidone for negative symptoms of schizophrenia, its MIN-301 program for Parkinson’s disease, and the financial resources supporting these efforts.
In annual reports on Form 10-K and quarterly reports on Form 10-Q, Minerva provides audited and interim financial statements, research and development and general and administrative expense details, information about its liability related to the sale of future royalties, and discussion of risks associated with clinical development and regulatory review. These filings also reference the Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for the roluperidone New Drug Application and the requirement for a confirmatory Phase 3 trial.
Current reports on Form 8-K capture material events such as the October 2025 securities purchase agreement for Series A Convertible Preferred Stock and warrants, the related private placement financing of up to $200 million in gross proceeds, and the appointment of new directors and consulting arrangements tied to roluperidone’s Phase 3 program. Definitive proxy statements on Schedule 14A outline proposals for stockholder votes, including increases in authorized common stock, approval of common shares issuable upon conversion of the Series A Preferred Stock, and amendments to the company’s equity incentive plan.
On Stock Titan, each 10-K, 10-Q, 8-K, DEF 14A and related document is accompanied by AI-generated highlights that explain key points in plain language, such as how Minerva plans to use proceeds from financings, how it describes the design of its confirmatory trial, and what changes are proposed to its capital structure. Real-time updates from EDGAR and easy access to insider- and governance-related disclosures allow users to review Minerva’s regulatory history and understand how clinical, financial and corporate decisions are documented over time.
Minerva Neurosciences, Inc. received an updated ownership report from Farallon-managed funds. The Farallon Funds together hold 2,365,000 common shares of Minerva and 5,000 Tranche A warrants, each warrant exercisable into one share of Series A convertible voting preferred stock.
Each Series A preferred share is convertible into 473 common shares, subject to a 9.99% Beneficial Ownership Limitation, which currently allows conversion into up to 2,174,854 common shares. Farallon Partners, L.L.C. reports beneficial ownership of 4,316,598 shares, or 9.5% of the common stock. Several Farallon individual reporting persons, including Joshua J. Dapice and others, each report beneficial ownership of 4,539,854 shares, or 9.99% of the class.
The amendment also notes that effective January 1, 2026, Avner A. Husen became a member or manager of the Farallon general partner entities, while effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles. The reporting group certifies the holdings are not for the purpose of changing or influencing control of Minerva.
Minerva Neurosciences is preparing a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, discussed at a virtual key opinion leader event. A supporting presentation is being made available on the company’s investor relations website.
The Phase 3 trial is expected to begin, including first patient screened, in the second quarter of 2026 and enroll 380 patients randomized 1:1 to placebo or a daily 64 mg dose of roluperidone. The primary goal is change from baseline at 12 weeks on the PANSS Marder negative symptoms factor score.
After 12 weeks, patients are expected to enter a 40‑week relapse assessment phase, receiving either roluperidone or antipsychotics. The company currently expects topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028, while highlighting numerous clinical, financial, and regulatory risks to these plans.
Minerva Neurosciences is asking stockholders at its virtual 2025 annual meeting on December 22, 2025 to approve several governance and financing-related actions. Stockholders will vote to elect two Class II directors, including incumbent Dr. Fouzia Laghrissi-Thode and recently appointed Dr. Inderjit Kaul, and to ratify Deloitte & Touche LLP as independent auditor. A key item would amend the certificate of incorporation to double authorized common stock from 125,000,000 to 250,000,000 shares, increasing total authorized capital stock to 350,000,000 shares. Another proposal seeks approval for the conversion of Series A Preferred Stock issued in an $80 million private placement, which could convert at 473 common shares per preferred share, with up to 94,600,000 common shares reserved for conversion assuming full warrant exercise. Minerva also seeks to add 12,500,000 shares to its 2013 equity plan, significantly expanding capacity for employee and director equity awards.
Minerva Neurosciences, Inc. expanded its Board of Directors to six members and appointed Inderjit Kaul, M.D., MPH as a Class II director, with his term running until the 2025 Annual Meeting or until a successor is elected and qualified. The appointment was made under a previously disclosed securities purchase agreement with certain investors.
Under the company’s non-employee director compensation plan, Dr. Kaul received an option to purchase 9,500 shares of common stock vesting quarterly over three years, plus a $40,000 annual cash retainer, prorated for 2025.
Separately, Minerva entered into a consulting agreement with Dr. Kaul, under which he will provide 25–30 hours of services per month at $450 per hour for an initial six-month term, renewable. Subject to shareholder and board approvals, he may receive an additional option representing 0.7% of the company’s defined Share Total, with vesting tied to key clinical milestones in the Phase 3 confirmatory trial of roluperidone in schizophrenia and subsequent safety data.
Minerva Neurosciences (NERV) reported a routine equity compensation grant to a non-employee director. On 11/14/2025, the director received a stock option to purchase 9,500 shares of Minerva common stock at an exercise price of $4.11 per share. The option vests in equal quarterly installments over three years, with the first installment vesting on February 14, 2026, as long as the individual continues to serve as a non-employee director on each vesting date. The option expires on November 13, 2035, giving a long-term incentive aligned with the company’s share performance.
Minerva Neurosciences, Inc. (NERV) reported a new insider filing on Form 3 for an individual serving as a director of the company. The event date for this initial ownership statement is 11/14/2025. According to the filing, the reporting person currently has no securities beneficially owned, meaning they do not hold Minerva Neurosciences stock or related derivative securities in their name or through indirect arrangements as of that date.
Minerva Neurosciences (NERV) reported Q3 2025 results and detailed a major post‑quarter financing. The company posted a net loss of $2.74 million as operating expenses fell year over year, driven by lower research and development and general and administrative costs. Cash, cash equivalents and restricted cash were $12.4 million as of September 30, 2025.
After quarter‑end, Minerva closed a private placement of Series A preferred stock and warrants for up to $200 million in gross proceeds. This included $80 million upfront for 80,000 Series A preferred shares, up to an additional $80 million from cash exercise of Tranche A warrants, and up to $40 million from Tranche B warrants tied to a milestone. The preferred stock automatically converts at $2.11 per share after stockholder approval, subject to a 9.99% beneficial ownership cap.
Management expects these funds to support the confirmatory Phase 3 trial of roluperidone, resubmission of its NDA, and U.S. launch readiness if approved. The liability related to the 2021 royalty sale remains at $60 million. Shares outstanding were 6,993,406 as of October 31, 2025.
Minerva Neurosciences (NERV) announced a private placement of up to $200 million, comprising 80,000 shares of Series A Convertible Preferred Stock at $1,000 per share ($80 million upfront) and warrants for additional preferred shares. Tranche A warrants are immediately exercisable for 80,000 Series A Preferred shares for cash ($80 million) until the tenth day after a public announcement of a statistically significant Phase 3 primary endpoint at 12 weeks. Tranche B warrants cover 40,000 preferred shares ($40 million), allow cashless exercise starting on the earlier of the milestone announcement or three years after closing, and expire four years after closing.
Conversion to common stock requires stockholder approval, after which each preferred share converts at a $2.11 per‑share conversion price, subject to a 9.99% beneficial ownership cap. If stockholder approval is not obtained within one year, the preferred shares are subject to redemption at the defined Liquidation Preference. Warrants may be forfeited if an investor engages in Short Sales within 48 months after closing. The company plans to use proceeds to fund the roluperidone Phase 3 confirmatory trial, NDA resubmission, U.S. launch readiness if approved, and for working capital.
The company agreed to file an S-3 resale registration after stockholder approval, expand the Board by up to three Vivo Capital designees, and form a scientific advisory board for the Phase 3 program.